Literature DB >> 32220178

[Biological Product Development Strategies for Prevention and Treatment of Coronavirus Disease 2019].

Cai-Xia Yan1, Jia Li1, Xin Shen1, Li Luo2, Yan Li1, Ming-Yuan Li3.   

Abstract

Coronavirus disease 2019 (COVID-19) caused by the novel coronavirus, also known as severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2), has become a Public Health Emergency of International Concern. Due to the large infection population, broad transmissibility and high mortality, it is urgent to find out the efficient and specific methods to prevent and treat COVID-19. As biological products have broadly applied in the prevention and treatment of severe epidemic diseases, they are promising in blocking novel coronavirus infection. According to the research advances of severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), we reviewed the potential application of biological products such as interferon, convalescent plasma, intestinal micro-ecological regulators, vaccines and therapeutic antibodies, etc. , on prevention and treatment of COVID-19. May this review be helpful for conquering COVID-19 in the near future. Copyright© by Editorial Board of Journal of Sichuan University (Medical Science Edition).

Entities:  

Keywords:  Biological products; COVID-19; MERS; SARS; SARS-CoV-2

Year:  2020        PMID: 32220178     DOI: 10.12182/20200360506

Source DB:  PubMed          Journal:  Sichuan Da Xue Xue Bao Yi Xue Ban        ISSN: 1672-173X


  2 in total

1.  Automatic pulmonary auscultation grading diagnosis of Coronavirus Disease 2019 in China with artificial intelligence algorithms: A cohort study.

Authors:  Hongling Zhu; Jinsheng Lai; Bingqiang Liu; Ziyuan Wen; Yulong Xiong; Honglin Li; Yuhua Zhou; Qiuyun Fu; Guoyi Yu; Xiaoxiang Yan; Xiaoyun Yang; Jianmin Zhang; Chao Wang; Hesong Zeng
Journal:  Comput Methods Programs Biomed       Date:  2021-10-27       Impact factor: 5.428

Review 2.  Understanding the COVID-19 pandemic from a gender perspective.

Authors:  Wen-Han Chang
Journal:  Taiwan J Obstet Gynecol       Date:  2020-09-11       Impact factor: 1.705

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.